Tag: neuroendocrine cancer clinical trials
Dr. Matthew H. Kulke to be Featured Guest for CCF’s Luncheon with the Experts
Matthew H. Kulke, MD, medical oncologist and hematologist, will be the featured guest for CCF’s Facebook Live Luncheon with the Experts on Thursday, May 27 from 12 noon to 1 pm, Eastern Time. Dr. Kulke is the Chief of Hematology/Oncology, Co-Director …
READ MORESTARTRK-2: A Basket Trial for Neuroendocrine Tumor Patients with Specific Gene Rearrangements
Precision medicine, molecular testing, basket studies, STARTRK-2 – it may sound like technology of the future but it is here today and it might be the answer to slowing or stopping tumor growth for neuroendocrine tumor (NET) patients who have specific…
READ MORE10 Highlights for the Carcinoid and Neuroendocrine Tumor Community
- PET/CT using Gallium-68 DOTATOC captures hidden source of neuroendocrine cancer. “An investigational molecular imaging technique could be the key to finding the elusive primary tumor, say presenters at the 2015 Annual Meeting of the Society
Gallium-68 Scan Coming to NOLANETS for Carcinoid and Neuroendocrine Tumor Patients
Dr. Eugene A. Woltering has announced that the Gallium-68 DOTATATE PET/CT scan is going to be available beginning in the summer of 2014 through The New Orleans Louisiana Neuroendocrine Tumor Specialists (NOLANETS) Neuroendocrine Tumor Program at …
READ MOREFirst U.S. Center to Enroll Patients in International, Multicenter Clinical Trial of Lu-177 Octreotate
Excel Diagnostics and Nuclear Oncology Center in Houston, Texas, is the first center in the United States to start recruiting patients in a multicenter randomized clinical trial of Lu-177 Octreotate in patients with progressive midgut carcinoid. …
READ MOREFDA Approves Amendment for PRRT Clinical Trial in Texas
BREAKING NEWS: The Food and Drug Administration (FDA) has just approved the RadioIsotope Therapy of America (RITA) Foundation’s amendment to the Investigational New Drug (IND) protocol for intra-hepatic artery administration of Lu-177 Octreotate…
READ MORENow Recruiting: Carcinoid Syndrome Patients to Participate in Clinical Trial
Ipsen is recruiting patients with a history of carcinoid syndrome to participate in a clinical study to evaluate the effect of Somatuline® Depot (Lanreotide Autogel), a somatostatin analog (SSTa) similar to octreotide, on the control of symptoms …
READ MOREFDA Approves Novel Radio-peptide Targeted Therapy Clinical Trial for Neuroendocrine Cancer: PRRT (Peptide Receptor Radionuclide Therapy)
For the first time in North America, neuroendocrine cancer patients will have the opportunity to participate in a clinical trial of Lutetieum-177 (LU-177)with Octreotate. Ebrahim S. Delpassand, MD, chief executive officer and medical director of…
READ MORE